Ascendis ready with clinical trial of another cancer drug

In January, Ascendis announced that its first potential cancer treatment was ready for clinical trials. The biotech company now seeks FDA approval to begin trials with a second cancer drug.

Photo: Sebastian Kahnert/AP/Ritzau Scanpix

Ambitions grow in the Danish biotech company Ascendis Pharma. On Tuesday, the company announced that it has applied for FDA approval of clinical trials with yet another potential drug for cancer treatment.

The drug candidate Transcon IL-2 β/γ, which is designed to improve cancer immunotherapy, is ready for a phase 1/2 clinical trial including patients with advanced cancer, pending FDA approval.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs